Jane Street Group LLC Reduces Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Jane Street Group LLC reduced its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 47.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 340,840 shares of the company's stock after selling 309,120 shares during the quarter. Jane Street Group LLC owned about 0.38% of Caribou Biosciences worth $542,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of CRBU. JPMorgan Chase & Co. grew its stake in Caribou Biosciences by 475.9% during the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Caribou Biosciences by 28.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock worth $3,360,000 after purchasing an additional 467,738 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Caribou Biosciences in the fourth quarter valued at approximately $288,000. Thrivent Financial for Lutherans boosted its position in Caribou Biosciences by 74.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company's stock valued at $297,000 after buying an additional 79,636 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in Caribou Biosciences in the 4th quarter worth approximately $102,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Price Performance

NASDAQ CRBU traded down $0.09 on Friday, hitting $1.08. The company had a trading volume of 1,260,218 shares, compared to its average volume of 1,454,292. The company's fifty day moving average price is $0.88 and its 200-day moving average price is $1.33. The company has a market capitalization of $99.98 million, a PE ratio of -0.65 and a beta of 2.36. Caribou Biosciences, Inc. has a 12-month low of $0.66 and a 12-month high of $3.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.35 million during the quarter, compared to analysts' expectations of $1.48 million. On average, sell-side analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and set a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $7.40.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.